Zobrazeno 1 - 10
of 324
pro vyhledávání: '"Gerald S. Falchook"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 2, Pp 89-96 (2024)
ABSTRACT: T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) is a receptor found on a multitude of immune cells and is commonly overexpressed in patients with cancer. Due to its selective expression in immune cells and its preliminar
Externí odkaz:
https://doaj.org/article/0f622e8b361e4e079d39071f0762d20e
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 1, Pp 53-66 (2024)
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal ant
Externí odkaz:
https://doaj.org/article/27adcada664f4bff8dfcb151f7a4acf5
Autor:
Kavanya Feustel, Gerald S. Falchook
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 58-67 (2022)
Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, th
Externí odkaz:
https://doaj.org/article/db81b3fade834669ac6b07a3a4dc1751
Autor:
Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 428-440 (2021)
Abstract Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial
Externí odkaz:
https://doaj.org/article/336092d3d9d74e2798fde9141c4ad366
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1183-1190 (2021)
Abstract Background Microsatellite‐stable (MSS) colorectal cancer (CRC) tends to be poorly immunogenic, with limited treatment options. In MSS CRC xenograft models, trifluridine/tipiracil (FTD/TPI) plus programed death 1 inhibitors resulted in syne
Externí odkaz:
https://doaj.org/article/406f196e6033499884ad7005c7ce68f1
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 16-22 (2020)
The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are a
Externí odkaz:
https://doaj.org/article/953c704e02074f5595cc1efcdade115b
Autor:
Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu, Razelle Kurzrock
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-12 (2019)
Abstract Background In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy, with overall surviva
Externí odkaz:
https://doaj.org/article/104ff192ed164bfea419fe086138f71a
Autor:
Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock
Publikováno v:
Cell Reports, Vol 6, Iss 2, Pp 377-387 (2014)
Despite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abno
Externí odkaz:
https://doaj.org/article/121a3483acb24454b24b119984535acb
Autor:
Rom Leidner, Carlo Bifulco, Israel Lowy, Gerald S. Falchook, Elizabeth Stankevich, Brian Piening, Matthew G. Fury
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies, high mutation burden has been a
Externí odkaz:
https://doaj.org/article/7bcb47495ed943a2a977969c25640d90
Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy, 3rd Edition, includes clinical trial results of more than 250 state-of-the-art targeted therapy and immunotherapy agents, providing a practical, intu